Investigational Drug BPM31510 Shows Encouraging Survival in Glioblastoma Trial -

Investigational Drug BPM31510 Shows Encouraging Survival in Glioblastoma Trial

Preliminary results from an ongoing phase 2 trial suggest that adding the investigational drug BPM31510 to standard chemoradiation may improve survival for patients with newly diagnosed glioblastoma. Among 39 evaluable patients, the median overall survival was 19.3 months, exceeding the survival typically seen with standard treatment alone. The greatest benefit was seen in patients with […]

Investigational Drug BPM31510 Shows Encouraging Survival in Glioblastoma Trial Read More »

Pembrolizumab Alone Improves Progression-Free Survival in dMMR Endometrial Cancer

Treatment / li001

Top-line results from the phase 3 KEYNOTE-C93 trial showed that pembrolizumab (Keytruda) alone significantly improved progression-free survival compared with standard carboplatin and paclitaxel chemotherapy in patients with mismatch repair-deficient (dMMR) advanced or recurrent endometrial cancer. The study enrolled 299 patients who had not received prior systemic chemotherapy. A positive trend in overall survival was also

Pembrolizumab Alone Improves Progression-Free Survival in dMMR Endometrial Cancer Read More »

Neoadjuvant Cemiplimab Shows Promise for Advanced Head and Neck Basal Cell Carcinoma

Clinical Trails / li001

A phase 2 trial found that neoadjuvant cemiplimab (Libtayo) produced encouraging results in 35 patients with locally advanced head and neck basal cell carcinoma who had not received Hedgehog inhibitor therapy. The treatment achieved a 60.1% objective response rate and a 91.4% disease control rate. Responding patients had an average tumor reduction of 70%, with

Neoadjuvant Cemiplimab Shows Promise for Advanced Head and Neck Basal Cell Carcinoma Read More »

FGFR Inhibitor AZD4547 Shows Promise Against Pancreatic Cancer and Liver Metastasis

Research Advances / li001

A new study suggests that the FGFR inhibitor AZD4547 may offer a new way to treat pancreatic cancer by targeting the tumor’s surrounding support cells rather than the cancer cells alone. Researchers found that the drug blocks the formation of inflammatory cancer-associated fibroblasts (iCAFs), which help tumors grow, spread, and evade the immune system. By

FGFR Inhibitor AZD4547 Shows Promise Against Pancreatic Cancer and Liver Metastasis Read More »

Study Reveals New Way to Boost Cancer Immunotherapy

Immunotherapy / li001

Researchers at MD Anderson Cancer Center have uncovered a strong connection between the immune system and cuproptosis, a newly discovered type of cell death caused by excess copper inside cells. The study found that immune cells called CD8-positive T cells help trigger cuproptosis in cancer cells. In turn, dying cancer cells release signals that attract

Study Reveals New Way to Boost Cancer Immunotherapy Read More »

Pembrolizumab Outperforms Chemotherapy in Advanced dMMR Endometrial Cancer

Treatment / li001

The phase 3 KEYNOTE-C93 trial showed that pembrolizumab (Keytruda) is more effective than standard chemotherapy as a first-line treatment for patients with advanced or recurrent mismatch repair-deficient (dMMR) endometrial cancer. The study included 299 patients who had not received previous chemotherapy for advanced disease or whose cancer returned more than six months after adjuvant treatment.

Pembrolizumab Outperforms Chemotherapy in Advanced dMMR Endometrial Cancer Read More »

Penpulimab Improves Disease-Free Survival in High-Risk Kidney Cancer

Clinical Trails / li001

A phase 2 trial found that adjuvant penpulimab-kcqx (Anikora) significantly improved disease-free survival in patients with very high-risk clear cell renal cell carcinoma after surgery. The study enrolled 174 patients after nephrectomy. Half received IV penpulimab every three weeks for up to 17 cycles, while the other half underwent standard observation. Penpulimab reduced the risk

Penpulimab Improves Disease-Free Survival in High-Risk Kidney Cancer Read More »

Phase 3 Trial Shows Survival Benefit for B7-H3 ADC in Small Cell Lung Cancer

Treatment / li001

The phase 3 ARTEMIS-008 trial found that risvutatug rezetecan (Ris-Rez), an investigational antibody-drug conjugate (ADC), significantly improved overall survival compared with standard chemotherapy (topotecan) in patients with advanced or relapsed small cell lung cancer (SCLC). The study met its primary goal, making Ris-Rez the first B7-H3-targeted ADC to show a survival benefit in a phase

Phase 3 Trial Shows Survival Benefit for B7-H3 ADC in Small Cell Lung Cancer Read More »

FDA Approves Gedatolisib for Advanced HR-Positive, HER2-Negative Breast Cancer

Drug Approvals / li001

The FDA has approved gedatolisib (Revtorpyk) in combination with fulvestrant (Faslodex), with or without palbociclib (Ibrance), for adults with hormone receptor (HR)-positive, HER2-negative advanced breast cancer without a PIK3CA mutation whose disease progressed during or after endocrine therapy for metastatic disease. Gedatolisib blocks multiple proteins in the PI3K/AKT/mTOR pathway, helping overcome treatment resistance and making it

FDA Approves Gedatolisib for Advanced HR-Positive, HER2-Negative Breast Cancer Read More »

Three-Drug Combination Shows Strong Activity in Rare Blood Cancer

Treatment / li001

A phase 2 clinical trial led by the Dana-Farber Cancer Institute found that a three-drug combination produced high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. The results were published in Blood. The study enrolled 27 patients with a median age of 70. Treatment combined tagraxofusp,

Three-Drug Combination Shows Strong Activity in Rare Blood Cancer Read More »